On February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics, Inc. effective March 12, 2024, to pursue other opportunities. Dr. Cooper?s resignation is voluntary and is not the result of any disagreement with the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.27 USD | -5.78% | -10.40% | +36.49% |
May. 08 | Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000 | MT |
May. 08 | Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.49% | 1.96B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KROS Stock
- News Keros Therapeutics, Inc.
- Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024